Identification of proteomic signatures of mantle cell lymphoma, small lymphocytic lymphoma, and marginal zone lymphoma biopsies by surface enhanced laser desorption/ionization-time of flight mass spectrometry

Abstract

Mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL), and marginal zone lymphoma (MZL) are small B-cell non-Hodgkin lymphomas (NHLs) that may be difficult to distinguish. In order to identify specific proteomic biomarkers, differential proteomic analysis of these three NHLs was performed using surface enhanced laser desorption/ionization-time of flight mass spectrometry (SELDI-TOF-MS). Whole cell lysates obtained from 18 MCL, 20 SLL, and 20 MZL biopsies were applied on two different ProteinChips (cationic and anionic). Hierarchical clustering and discriminating scores combined with an innovative bio-informatics microdissection strategy allowed us to distinguish specific lymphoma proteomic signatures based on the expression of 37 protein peaks. SELDI-assisted protein purification combined with nano-liquid chromatography (LC) quadrupole-time of flight tandem mass spectrometry (Q-TOF MS/MS) was used to identify proteins overexpressed in both MCL and SLL tumors. Among them two histones, H2B and H4, were identified in MCL tumor biopsies and the signal recognition particle 9 kDa protein, SRP9, in SLL tumor biopsies.

New developments in the pathology of malignant lymphoma. A review of the literature published from February 2011 to August 2011

“…Rolland et al [70] use the same approach analyzing the protein profiles with SELDI-TOF-MS on 18 cases of MCL, 20 SLL, and 20 MZL. Based on an new bioinformatics approach, they could reliably discriminate these samples based on 37 peaks.…”

Proteomic approaches to the study of malignant lymphoma: Analyses on patient samples

“…Another issue in lymphomas is the distinction between lymphoma entities that currently is difficult to distinguish with the present diagnostic tools. Rolland et al elaborated on the difficulties in classification of MCL, marginal zone lymphoma (MZL), and SLL, which they investigated by SELDI‐TOF‐MS, with subsequent identification of upregulated proteins specific for MCL (i.e., histone 2B [H2B], H4) and for SLL (i.e., signal recognition particle 9 kDa) were identified by LC‐MS/MS . The high expressions of H2B and H4 in MCL were further confirmed by immunohistochemistry (IHC) in an additional cohort of formalin‐fixed paraffin‐embedded (FFPE) tissues containing MCL, MZL, and SLL .…”

Potential role of proteomics in the diagnosis of lymphoma: a meta‐analysis

“…It analyses small volumes of clinical samples without destroying the proteins to be detected and is capable of examining proteins and peptides, which are not available for conventional methods [6,7]. At present, there are many exciting SELDI applications, which have been described by numerous laboratories, especially in studying cancers of various organs, including prostate [10], liver [11], pancreas [12], ovary [13], breast [14], lung [15], colon [16] and others [17,18].…”